Delayed GN Hearing device sent for FDA evaluation
Hearing device Jabra Enhance Plus, which GN Hearing is hoping will open up a new market, has been submitted to the US Food and Drug Administration for assessment. Earlier this month, product launch delays led to the head of reasearch and development being let go.
BY MIKKEL AABENHUS HEMMINGSEN, ANDREAS LØNSTRUP, TRANSLATED BY DANIEL PEDERSEN
The launch of the new hearing device Jabra Enhance Plus, which is developed by GN Hearing, now depends on the US Food and Drug Administration (FDA), as the company has sent the product off for evaluation, CEO Gitte Aabo tells MedWatch in an interview.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
New GN device to open giant market for mild hearing loss
For subscribers
